Erste Asset Management GmbH Acquires 3,149 Shares of Biogen Inc. $BIIB

Erste Asset Management GmbH increased its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 6.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 48,734 shares of the biotechnology company’s stock after buying an additional 3,149 shares during the quarter. Erste Asset Management GmbH’s holdings in Biogen were worth $8,618,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. lifted its position in shares of Biogen by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock worth $3,070,514,000 after buying an additional 157,857 shares during the last quarter. Geode Capital Management LLC raised its position in Biogen by 3.2% in the fourth quarter. Geode Capital Management LLC now owns 4,199,399 shares of the biotechnology company’s stock valued at $736,435,000 after purchasing an additional 130,618 shares during the last quarter. Norges Bank bought a new position in Biogen in the fourth quarter valued at about $464,408,000. Invesco Ltd. raised its position in Biogen by 4.2% in the third quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock valued at $338,731,000 after purchasing an additional 98,001 shares during the last quarter. Finally, AQR Capital Management LLC raised its position in Biogen by 30.7% in the third quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock valued at $248,809,000 after purchasing an additional 418,776 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

BIIB has been the subject of several research reports. Truist Financial dropped their target price on Biogen from $193.00 to $189.00 and set a “hold” rating for the company in a research report on Monday, April 13th. Wedbush increased their target price on Biogen from $191.00 to $196.00 and gave the company a “neutral” rating in a research report on Thursday, April 30th. Mizuho increased their target price on Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a research report on Tuesday, February 10th. TD Cowen increased their target price on Biogen from $175.00 to $215.00 and gave the company a “buy” rating in a research report on Monday, February 9th. Finally, Argus upgraded Biogen to a “hold” rating in a research report on Thursday, April 9th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $217.26.

Biogen Trading Down 1.4%

Shares of BIIB stock opened at $192.62 on Tuesday. The stock has a market cap of $28.44 billion, a price-to-earnings ratio of 20.67 and a beta of 0.20. The stock has a 50-day moving average of $187.63 and a 200-day moving average of $183.63. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 1-year low of $121.05 and a 1-year high of $205.97.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, beating the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities research analysts forecast that Biogen Inc. will post 14.18 earnings per share for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.